TDMS Study 05133-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
ACETONITRILE
NTP Experiment-Test: 05133-04 Report: PEIRPT05
Study Type: CHRONIC Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
Facility: Battelle Northwest
Chemical CAS #: 75-05-8
Lock Date: 07/17/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 6 5 8 5
Moribund Sacrifice 15 12 13 13
Accidently Killed 1
Survivors
Natural Death 1
Terminal Sacrifice 28 32 29 32
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (52) (55) (51) (56)
Intestine Large, Cecum (55) (56) (58) (56)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (52) (54) (54) (55)
Intestine Small, Jejunum (54) (56) (56) (57)
Intestine Small, Ileum (55) (57) (55) (57)
Liver (59) (60) (60) (59)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 5 (8%) 5 (8%) 4 (7%) 4 (7%)
Hepatocellular Carcinoma, Multiple 2 (3%) 1 (2%) 2 (3%) 1 (2%)
Hepatocellular Adenoma 3 (5%) 9 (15%) 7 (12%) 4 (7%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%) 2 (3%) 2 (3%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 1 (2%)
Mesentery (10) (16) (7) (5)
Carcinoma, Metastatic, Ovary 1 (6%)
Sarcoma Stromal, Metastatic, Uterus 1 (6%)
Fat, Carcinoma, Metastatic, Pancreas 1 (14%)
Fat, Hemangioma 1 (6%)
Fat, Histiocytic Sarcoma 1 (6%)
Pancreas (59) (59) (60) (58)
Adenocarcinoma 1 (2%)
Fibrosarcoma 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Salivary Glands (59) (60) (60) (59)
Stomach, Forestomach (59) (60) (60) (58)
Carcinoma, Metastatic, Pancreas 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 3 (5%)
Page 2
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (59) (58) (60) (58)
Carcinoma, Metastatic, Pancreas 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (59) (60) (59) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (59) (60) (59)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (58) (58) (60) (58)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (3%)
Islets, Pancreatic (59) (59) (60) (57)
Adenoma 2 (3%)
Pituitary Gland (58) (59) (60) (58)
Pars Distalis, Adenoma 14 (24%) 14 (24%) 15 (25%) 6 (10%)
Pars Intermedia, Adenoma 2 (3%)
Thyroid Gland (59) (58) (60) (59)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (3%) 3 (5%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (1)
Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (58) (57) (58) (57)
Arrhenoblastoma NOS 1 (2%)
Cystadenoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Yolk Sac Carcinoma 1 (2%)
Uterus (59) (59) (60) (59)
Page 3
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 2 (3%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (3%) 2 (3%) 3 (5%) 3 (5%)
Sarcoma Stromal 1 (2%)
Cervix, Fibroma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (59) (59) (60) (59)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Lymph Node (7) (9) (9) (1)
Pancreatic, Histiocytic Sarcoma 1 (14%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Bronchial (48) (54) (51) (46)
Carcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 2 (4%)
Lymph Node, Mandibular (42) (45) (52) (41)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (54) (53) (57) (51)
Carcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Lymph Node, Mediastinal (43) (43) (44) (41)
Histiocytic Sarcoma 2 (5%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Spleen (59) (59) (60) (58)
Hemangiosarcoma 2 (3%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Thymus (54) (58) (56) (51)
Sarcoma Stromal, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (59) (57) (60) (57)
Adenoacanthoma 1 (2%)
Adenocarcinoma 3 (5%) 3 (5%) 1 (2%)
Skin (59) (60) (60) (59)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (3%)
Subcutaneous Tissue, Sarcoma Stromal,
Metastatic, Uterus 1 (2%)
Page 4
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (59) (60) (60) (60)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (59) (60) (60) (59)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (59) (60) (60) (59)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 6 (10%) 2 (3%) 4 (7%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 2 (3%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Nose (59) (60) (60) (59)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (1) (2) (1)
Adenocarcinoma 1 (50%) 1 (100%)
Adenoma 3 (100%) 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (59) (60) (58)
Histiocytic Sarcoma 2 (3%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (57) (57) (59) (57)
Page 5
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Lymphocytic 6 (10%) 10 (17%) 9 (15%) 3 (5%)
Lymphoma Malignant Mixed 5 (8%) 7 (12%) 7 (12%) 11 (18%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 38 40 33
Total Primary Neoplasms 74 66 71 52
Total Animals with Benign Neoplasms 29 27 27 19
Total Benign Neoplasms 40 38 38 24
Total Animals with Malignant Neoplasms 24 23 27 24
Total Malignant Neoplasms 33 28 33 28
Total Animals with Metastatic Neoplasms 3 3 3 3
Total Metastatic Neoplasm 3 12 9 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 13 14 16 6
Natural Death 5 4 2 1
Survivors
Terminal Sacrifice 32 32 32 43
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (57) (60) (58) (59)
Anus, Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (56) (58) (58) (58)
Adenoma 1 (2%)
Intestine Small, Jejunum (55) (58) (57) (59)
Carcinoma 1 (2%) 1 (2%)
Liver (60) (60) (59) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 2 (3%) 2 (3%)
Hepatocellular Carcinoma 4 (7%) 11 (18%) 7 (12%) 6 (10%)
Hepatocellular Carcinoma, Multiple 4 (7%) 3 (5%) 6 (10%) 1 (2%)
Hepatocellular Adenoma 11 (18%) 11 (18%) 15 (25%) 10 (17%)
Hepatocellular Adenoma, Multiple 4 (7%) 2 (3%) 5 (8%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Bile Duct, Carcinoma 1 (2%)
Mesentery (3) (3) (3) (3)
Sarcoma, Metastatic, Skin 1 (33%)
Fat, Hemangioma 1 (33%) 1 (33%)
Pancreas (59) (60) (58) (60)
Adenocarcinoma 1 (2%)
Salivary Glands (60) (60) (58) (60)
Stomach, Forestomach (59) (60) (58) (60)
Squamous Cell Papilloma 1 (2%) 2 (3%)
Stomach, Glandular (59) (60) (58) (60)
Carcinoma, Metastatic, Pancreas 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (58) (60) (58) (60)
Adenoma 1 (2%)
Capsule, Adenoma 1 (2%) 4 (7%) 1 (2%)
Adrenal Medulla (59) (60) (57) (60)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (57) (60) (58) (60)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (56) (58) (56) (59)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (59) (60) (58) (60)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Testes (60) (60) (59) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (59) (60) (58) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (3) (2) (2)
Lymph Node, Bronchial (41) (44) (45) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Lymph Node, Mandibular (43) (39) (36) (44)
Lymph Node, Mesenteric (56) (59) (57) (58)
Hemangiosarcoma 1 (2%)
Lymph Node, Mediastinal (47) (45) (44) (40)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangiosarcoma 1 (3%)
Sarcoma, Metastatic, Skin 1 (2%)
Page 9
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (59) (60) (58) (60)
Hemangiosarcoma 1 (2%)
Thymus (53) (54) (48) (57)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (59) (59) (60)
Basal Cell Carcinoma 1 (2%)
Prepuce, Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (58) (60)
Alveolar/Bronchiolar Adenoma 5 (8%) 11 (18%) 8 (14%) 20 (33%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 1 (2%) 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 6 (10%) 7 (12%) 4 (7%) 4 (7%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (7%) 2 (3%) 5 (9%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (5) (1) (2)
Adenoma 5 (100%) 4 (80%) 1 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (60) (58) (60)
Pelvis, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 2 (3%) 3 (5%) 3 (5%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05133-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACETONITRILE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 06:55:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 50 PPM 100 PPM 200 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 44 40 38
Total Primary Neoplasms 60 71 59 62
Total Animals with Benign Neoplasms 26 29 28 31
Total Benign Neoplasms 36 39 34 41
Total Animals with Malignant Neoplasms 21 27 19 18
Total Malignant Neoplasms 24 32 25 21
Total Animals with Metastatic Neoplasms 5 3 5
Total Metastatic Neoplasm 7 7 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------